Back to Search
Start Over
RAS mutations: impact on treatment outcome
- Source :
- Colorectal Cancer. 2:525-534
- Publication Year :
- 2013
- Publisher :
- Future Medicine Ltd, 2013.
-
Abstract
- SUMMARY RAS proteins belong to the MAPK network, an essential pathway for maintenance of normal vital processes such as proliferation and differentiation. RAS mutations are observed in 30–50% of colorectal carcinomas. The MAPK pathway and RAS proteins are part of a complex system that mediate signaling from the EGF receptors (EGFRs). Our review discusses the most recent evidence highlighting the role of KRAS mutations in patients who are offered anti-EGFR therapy. Furthermore, we discuss emerging evidence of the role of other predictive markers such as PI3K, PTEN, BRAF, NRAS, MET, IGFR-1 and p53 in patients who are receiving anti-EGFR therapy.
Details
- ISSN :
- 17581958 and 1758194X
- Volume :
- 2
- Database :
- OpenAIRE
- Journal :
- Colorectal Cancer
- Accession number :
- edsair.doi...........2feba1456a65aae033e6497a45d9e5c0